OncoMatch/DIPG / Diffuse Midline Glioma/H3 K27M
DIPG / Diffuse Midline GliomaH3 K27M Clinical Trials
H3 K27M mutations in H3-3A (or H3C2/H3C3) define diffuse midline glioma — H3 K27-altered, a WHO grade 4 entity encompassing DIPG — and occur in >70% of pontine tumors in children and young adults. Dordaviprone (Modeyso; formerly ONC201), a protease activator, received FDA accelerated approval in August 2025 for adult and pediatric patients aged ≥1 year with H3 K27M-mutant diffuse midline glioma with disease progression following prior therapy; ORR was 22% and median DOR was 10.3 months. Trials investigate dordaviprone combinations, radiation sensitizers, and novel H3 K27M-targeted immunotherapy approaches.
Top recruiting H3 K27M DIPG / Diffuse Midline Glioma trials
Ranked by phase and US site count.
See all trials matched to your profile →H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Shenzhen Geno-Immune Medical Institute
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Sabine Mueller, MD, PhD
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Emory University
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine